top of page
MiRaDor
OFFICIAL TITLE: A PROOF-OF-CONCEPT STUDY TO EVALUATE TREATMENTS' EFFICACY BY MONITORING MINIMAL RESIDUAL DISEASE USING CTDNA IN HR-POSITIVE/HER2-NEGATIVE EARLY BREAST CANCER POPULATION.
HR+/HER2- early breast cancer with high risk of relapse
II
40 (possible 20 patient expansion cohort)
67
Spain, England, Brazil, Peru, Italy, France, Poland, Greece
Set-up
CLINICAL TRIAL DETAILS
THE PRIMARY OBJECTIVE IS TO EVALUATE THE EFFICACY IN TERMS OF RATE OF PATIENTS WITH A 90% DECREASE OR CLEARANCE IN BASELINE CTDNA AT THREE MONTHS AFTER RANDOMIZATION.
IN ADDITION, THE STUDY WILL ASSESS THE EFFICACY IN TERMS OF THE RATE OF PATIENTS WITH A 90% DECREASE IN BASELINE CTDNA AT SIX, NINE AND TWELVE MONTHS, AS WELL AS ASSESS THE RATE OF PATIENTS WITH A 50% AND 70% DECREASE IN BASELINE CTDNA AT THREE, SIX, NINE AND TWELVE MONTHS.
MiRaDor AT CLINICALTRIALS.GOV
TUMOR TYPE
PHASE
N
SITES
COUNTRY
STATUS
TRIAL RESUME
PRESS RELEASE
SCIENTIFIC IMPACT
BLOG ARTICLES RELATED
MiRaDor SITES
SPAIN
Hospital Universitario Clínico San Cecilio de Granada
SPAIN
Hospital Clínic i Provincial de Barcelona
SPAIN
Hospital Arnau de Vilanova de Valencia
SPAIN
Complejo Hospitalario de Jaén
SPAIN
Hospital General Universitario Dr. Balmis
SPAIN
Hospital Universitario La Ribera, Alzira
SPAIN
Hospital Virgen de los Lirios
SPAIN
Hospital Marina Salud de Denia
SPAIN
Hospital de Sagunto
SPAIN
Hospital Universitario Virgen del Rocío
SPAIN
Hospital Universitari Sant Joan de Reus
SPAIN
Hospital Universitari Dexeus
SPAIN
Hospital Universitario de Basurto
SPAIN
Hospital Universitario Arnau de Vilanova de Lleida
SPAIN
Hospital de Manises
ENGLAND
Barts Cancer Institute
BRAZIL
Centro de Câncer de Brasília
BRAZIL
Belo Horizonte (Oncocentro)
bottom of page